Posted by Michael Wonder on 10 Nov 2021
EMA starts evaluating use of COVID-19 vaccine Spikevax in children aged 6 to 11
10 November 2021 - EMA has started evaluating an application to extend the use of Moderna’s COVID-19 vaccine, Spikevax, to children aged 6 to 11.
EMA’s CHMP will review the data on the vaccine, including results from an ongoing clinical study involving children aged 6 to 11, in order to decide whether to recommend extending its use.
